Drugs that contain Gilteritinib Fumarate

1. Drug name - XOSPATA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Jan, 2031

(8 years from now)

CN102421761B ASTELLAS Two Heterocyclic Carboxamide Compounds
May, 2030

(7 years from now)

CN102421761A ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

IN201108996P4 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

IN292990B ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP3009428A1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP3009428B1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508B9 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508A1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508B1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508A4 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487491 ASTELLAS Diamino heterocyclic carboxamide compound Jul, 2030

(7 years from now)

US10786500 ASTELLAS Stable pharmaceutical composition for oral administration Jul, 2036

(13 years from now)

Treatment: Treatment of acute myeloid leukemia (aml)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.